Company: HSDTW
Filing Date: 2025-07-07
Form Type: 424B5
Source: 0001104659-25-066159
Chunk: 0

Company: Solana Co
Filing Date: 2025-07-07
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS

#### Filed Pursuant to Rule 424(b)(5)

#### Registration No. 333-270433

### PROSPECTUS SUPPLEMENT
**(To Prospectus Supplements dated June 23, 2023 and March 26, 2025**

#### and Prospectus dated May 25, 2023)

#### Helius Medical Technologies, Inc.

#### Up to $25,000,000Class A Common Stock
**This prospectus supplement amends and supplements the prospectus supplements, dated June 23, 2023 and March 26, 2025 (the “Prior Prospectus Supplement”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-270433), relating to the offer and sale of shares of our Class A common stock (“common stock”) pursuant to the Sale Agreement, dated June 23, 2023 (the “Sales Agreement”), with Roth Capital Partners, LLC (the “Agent”). We are filing this prospectus supplement to increase the maximum offering size to $25.0 million from the date hereof. This prospectus supplement should be read in conjunction with the Prior Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus Supplement.

Our common stock trades on the Nasdaq Capital Market under the symbol “HSDT.” On July 3, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $9.40 per share.

We will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation at a commission rate up to 3% of the aggregate gross sales price of the shares sold. In connection with the sale of our common stock on our behalf, the Agent may be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the Agent may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act.

We are a “smaller reporting company” as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. See “Prospectus Summary — Implications of Being a Smaller Reporting Company.” This prospectus complies with the